Sermorelin: The First GHRH Analog in Clinical Use

What sermorelin is

Sermorelin is a 29 amino acid synthetic peptide corresponding to the first 29 residues of native human growth hormone-releasing hormone (GHRH), a 44 amino acid hypothalamic peptide. The compound carries a C-terminal amide modification in place of the free acid that would be present on a truncated native sequence. That modification is important for receptor binding: the C-terminal amide is required for full agonist activity at the GHRH receptor.

Early research in the 1980s established that the biological activity of GHRH was concentrated in its N-terminal segment. Studies by Rivier and colleagues at the Salk Institute and by Guillemin's group demonstrated that peptides corresponding to roughly the first 29 amino acids of GHRH retained the ability to stimulate growth hormone release from pituitary cells. This finding made sermorelin a tractable drug candidate: a shorter peptide is easier and less expensive to synthesize than the full 44 amino acid sequence.

The compound is also referred to in literature as GHRH(1-29)NH2, reflecting its structure: residues 1 through 29 of GHRH with a C-terminal amide. It is chemically distinct from tesamorelin, which is based on the full 44 amino acid sequence and carries an N-terminal fatty acid modification for improved stability. Sermorelin has a plasma half-life of approximately 11 to 12 minutes as documented in the Geref prescribing information, making it considerably shorter-lived than tesamorelin or the long-acting GHRH-based fragment CJC-1295 DAC.

How sermorelin works

Sermorelin acts as an agonist at the pituitary GHRH receptor, a G protein-coupled receptor that, when activated, triggers the synthesis and release of growth hormone from somatotroph cells. The downstream cascade follows the normal GH axis: released growth hormone acts on peripheral tissues directly and also stimulates the liver to produce insulin-like growth factor 1 (IGF-1), which mediates many of GH's anabolic and metabolic effects.

Because sermorelin acts upstream at the pituitary rather than replacing growth hormone directly, it preserves the feedback architecture of the GH axis. Somatostatin, the hypothalamic hormone that inhibits GH release, continues to function normally. This means that sermorelin-stimulated GH release follows a physiological pulsatile pattern rather than producing the sustained supraphysiological exposure that can occur with exogenous recombinant GH.

• •Sermorelin binds the pituitary GHRH receptor (GHRHR) and stimulates cAMP production in somatotrophs
• •Resulting GH release is pulsatile, mimicking the normal physiological pattern rather than producing a sustained spike
• •Downstream IGF-1 production in the liver rises in proportion to GH release
• •The somatostatin feedback system remains intact, providing a natural ceiling on GH elevation
• •In adipose tissue, GH promotes lipolysis; in muscle, it supports protein synthesis and nitrogen retention

FDA approval and the Geref history

Sermorelin was approved by the FDA in November 1997 under the brand name Geref Injection, manufactured by Serono Laboratories. The approved indication was long-term treatment of idiopathic growth hormone deficiency in children who demonstrated inadequate GH secretion in stimulation testing. The rationale was that stimulating the child's own pituitary with a GHRH analog could restore more physiologically normal GH release compared to daily injections of recombinant GH.

The approval made sermorelin the first synthetic GHRH analog to clear the FDA review process, predating tesamorelin's approval by 13 years. At the time, the availability of recombinant GH as an established treatment created a crowded competitive landscape. Serono marketed Geref alongside its own recombinant GH product Saizen, which may have contributed to the commercial calculus that followed.

In 2002, Serono voluntarily withdrew Geref Injection from the US market. The company cited manufacturing decisions rather than safety concerns; no regulatory action compelled the withdrawal. The move left sermorelin without an FDA-approved commercial product in the United States. Compounding pharmacies subsequently became the primary source of sermorelin in clinical settings, particularly as interest in GHRH analogs for adult use grew in the anti-aging medicine community.

Research in adult growth hormone insufficiency

Growth hormone output declines substantially with age, a phenomenon sometimes called somatopause. Published data suggest that GH pulse amplitude falls by roughly half between young adulthood and middle age, with corresponding declines in IGF-1. Age-related GH decline is associated with changes in body composition, including increased visceral fat, reduced lean mass, and decreased bone density, though establishing causation rather than correlation is methodologically difficult in aging research.

A review by Walker published in Clinical Interventions in Aging in 2006 examined the evidence base for sermorelin as an approach to adult-onset growth hormone insufficiency. Walker argued that stimulating endogenous GH release with a GHRH analog preserved physiological pulsatility and the somatostatin feedback system in a way that recombinant GH administration does not, and that this physiological pattern might offer a better safety profile for long-term use in aging adults. The paper was a clinical commentary rather than a randomized trial, but it articulated the mechanistic rationale that has shaped subsequent research interest.

Clinical studies in adults have examined sermorelin's effects on IGF-1 levels, body composition, and tolerability. In general, these studies confirm that sermorelin raises IGF-1 toward younger reference ranges in adults with low baseline levels, and that body composition changes including modest reductions in fat mass and improvements in lean mass have been observed in some studies. The evidence base is considerably smaller and less rigorous than the trial programs behind tesamorelin or the approved recombinant GH products, and most published work involves short durations and limited sample sizes.

• •IGF-1 normalization in adults with subnormal baseline levels is a consistent finding across small published studies
• •Body composition effects have been reported in some studies but are less reliably demonstrated than in tesamorelin trials
• •The short plasma half-life of sermorelin requires more frequent dosing than longer-acting GHRH analogs
• •No large randomized controlled trials comparable to the Egrifta program have been conducted with sermorelin in adults
• •Research use framing applies to sermorelin outside the historical pediatric indication, as there is no approved adult indication

Safety and tolerability context

The safety profile of sermorelin in its approved pediatric use was characterized by a relatively modest adverse event burden. The Geref prescribing information listed local injection site reactions as the most common adverse events, occurring in a meaningful proportion of patients. Flushing and headache were also reported. These effects are consistent with those seen with other GHRH analogs and are generally transient.

Because sermorelin raises IGF-1, the broader safety considerations that apply to GH axis stimulation are relevant. Elevated IGF-1 has been associated in observational studies with certain cancer risks, though the causal relationship is debated and the magnitude of any risk from short-term therapeutic IGF-1 elevation is not well quantified. The pulsatile, feedback-preserved GH release pattern produced by GHRH analogs is often cited as a theoretical safety advantage over exogenous recombinant GH, where sustained supraphysiological levels are more likely.

For individuals with active malignancy or a history of growth-dependent tumors, GHRH-class compounds are generally contraindicated in clinical practice. The same precaution extends to hypothyroidism, which can blunt the GH response to GHRH stimulation, and to patients taking glucocorticoids, which are known to inhibit GH axis function. Because sermorelin has no current FDA-approved commercial product, clinical use outside controlled research settings is largely through compounding channels, and oversight varies.

Sermorelin in the context of the growth hormone axis compounds

Sermorelin occupies a specific position in the landscape of GH axis-active research compounds. It predates and mechanistically resembles tesamorelin, but the two differ in half-life, structural modification, and clinical evidence depth. Tesamorelin has Phase 3 trial data and an FDA-approved indication; sermorelin's pediatric approval was withdrawn over two decades ago and the adult evidence base is thin by comparison.

CJC-1295, another GHRH analog studied in the research peptide space, uses a drug-affinity complex (DAC) modification to extend its half-life to days rather than minutes, making it structurally and pharmacokinetically quite different from sermorelin despite both being GHRH-class peptides. Ipamorelin acts through the ghrelin receptor pathway rather than the GHRH receptor, making it complementary rather than redundant. Researchers interested in sermorelin typically encounter it in the context of these related compounds.

Compound reference pages